Journal of Medicinal Chemistry p. 234 - 240 (1995)
Update date:2022-09-26
Topics:
Houlihan, William J.
Munder, Paul G.
Handley, Dean A.
Cheon, Seung H.
Parrino, Vincent A.
A series of 5-aryl-2,3-dihydroimidazo<2,1-a>isoquinolines previously reported to be platelet activating factor (PAF) receptor antagonist were evaluated for potential antitumor activity.Several compounds, such as the 5-(4'-tert-butylphenyl) (65), 5-<4'-(trimethylsilyl)phenyl> (69), and 5-(4'-cyclohexylphenyl) (71) analogs showed very good cytotoxicity against several tumor cell lines. 5-<4'-(Piperidinomethyl)phenyl>-2,3-dihydroimidazo<2,1-a>isoquinoline (SDZ 62-434, 53) was more effective on a milligram per kilogram basis than the clinical cytostatic agent edelfosine (1) in increasing survivors and decreasing tumor volume in the oral mouse Meth A fibrosarcoma assay.It was selected for further development and is currently in phase I clinical trials in cancer patients.
View MoreJiaxing Anrui Material Technology Co., Ltd.
Contact:86-573-82651652 13305832579
Address:Room 407, Technology Building, 1369 Chennan Road, Jiaxing City, Zhejiang, China
Zhejiang Chemline International Co., Ltd.
Contact:+86-571-88062298
Address:Hengdian Industry Area, Dongyang, Zhejiang, China
Sinoway International (Jiangsu) Co., Ltd.
Contact:+86-25-86630167
Address:17 Beijing Road (West), Nanjing, China
Contact:+86-25-85281586
Address:13F,Bld2#,South of Longpan Road
Chuzhou Baiao Biologhy S&T Co., Ltd.
Contact:+86-25-83212599；+86-25-83212699 13705185959
Address:Room 905, Tianzheng International Platza, No.399, Zhongyang Road ,Nanjing, Jiangsu Province, China
Doi:10.1021/jo00310a014
(1990)Doi:10.1016/j.chempr.2017.10.007
(2017)Doi:10.1021/acs.jmedchem.0c00566
(2020)Doi:10.1246/bcsj.59.1277
(1986)Doi:10.1016/j.ejmech.2011.01.051
(2011)Doi:10.1021/ja2026882
(2011)
